Log In
BCIQ
Print this Print this
 

CK-101, RX518

  Manage Alerts
Collapse Summary General Information
Company Suzhou NeuPharma Co. Ltd.
DescriptionThird-generation covalent inhibitor of EGFR-activating mutations and the T790M EGFR resistance mutation
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerCheckpoint Therapeutics Inc.;
Fortress Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today